Cite
HARVARD Citation
Hata, A. et al. (n.d.). 1501TiPAfatinib (AFA) plus bevacizumab (BEV) combination after osimertinib (OSIME) failure for aDvanced EGFR-mutant non-small cell lung cancer (NSCLC): A multicenter prospective single arm phase II study (ABCD-study). Annals of oncology. p. . [Online].